Lariago-DS Tablet (Chloroquine 500mg)

What is Lariago-DS Tablet (Chloroquine 500mg)?

Lariago-DS Tablet (Chloroquine 500mg) is a prescription medication containing chloroquine phosphate, an antimalarial agent used to prevent and treat malaria caused by mosquito bites in regions where malaria is common. It works by interfering with the growth of parasites in the red blood cells. Though primarily used for malaria, it may also be prescribed off-label for certain autoimmune diseases like rheumatoid arthritis or lupus under strict medical guidance. This medication requires a valid prescription and should be taken exactly as directed by a healthcare provider.

Key features

• Active Ingredient — Chloroquine phosphate 500mg per tablet.
• Prescription Required — Not available over-the-counter; must be used under medical supervision.
• Malaria Prevention — Effective for prophylaxis in malaria-endemic regions.
• Oral Administration — Taken by mouth, usually once weekly during travel or as prescribed.
• Established Medication — Long-standing use in tropical medicine and infectious disease control.
• Stable Storage — No refrigeration needed; store at room temperature away from moisture.
• Brand Consistency — Manufactured to meet pharmaceutical quality standards for reliability.

Who is Lariago-DS Tablet (Chloroquine 500mg) for?

This tablet is intended for adults and children over a specified weight threshold traveling to or living in areas with risk of malaria transmission. It is also prescribed to select patients with autoimmune disorders when other treatments are unsuitable. It is not suitable for self-medication and must be used only under the supervision of a licensed healthcare provider due to potential side effects and drug interactions.

How does Lariago-DS Tablet (Chloroquine 500mg) compare?

Compared to newer antimalarials like atovaquone-proguanil or doxycycline, chloroquine is less effective in regions with widespread resistance, such as parts of Africa and Southeast Asia. However, it remains a cost-effective and accessible option in areas where the Plasmodium parasite remains sensitive. Unlike fast-acting emergency treatments, Lariago-DS is used for prevention and acute treatment in specific cases. It differs from artemisinin-based combination therapies (ACTs), which are now first-line treatments for falciparum malaria. For autoimmune use, it's an alternative to hydroxychloroquine, though with a slightly different safety profile.